PharmaNet Development Group Announces Observational Research Survey

Results to be released in November

Published: Monday, October 11, 2010 - 11:36

(PharmaNet Development Group: Princeton, NJ) -- PharmaNet Development Group Inc., a provider of drug development services to the pharmaceutical, biotechnology, generic drug, and medical device industries, has released a new survey on pharmaceutical observational research, the fourth in an ongoing series. The survey is open to all in the industry with an interest in observational research and can be accessed here through Oct. 31.

“Pharmaceutical companies are increasingly looking to prospective observational research for compiling real-world data on post-approval clinical performance, economic value, patient quality of life, and product safety,” says Jeff Trotter, executive vice president, Phase IV Development, and creator of the survey. “While the scientific community excels at designing and executing controlled clinical trials, there may be less appreciation for the value of observational studies. The goal of the survey is to identify underlying issues in order to move toward more appropriately designed studies that improve the understanding of product performance among clients, regulators, policymakers, physicians, and patients.”

Previous surveys have revealed that drug-development organizations can benefit from broader cross functional collaboration and consensus on the strategy for observational research. The latest survey will continue to track evolving trends.

The results of this survey, plus the findings identified in previous surveys, are expected to be released in November. If you are interested in receiving the findings report or receiving more information on pharmaceutical observational research, contact aserody@pharmanet.com.

Quality Digest does not charge readers for its content. We believe that industry news is important for you to do your job, and Quality Digest supports businesses of all types.

However, someone has to pay for this content. And that’s where advertising comes in. Most people consider ads a nuisance, but they do serve a useful function besides allowing media companies to stay afloat. They keep you aware of new products and services relevant to your industry. All ads in Quality Digest apply directly to products and services that most of our readers need. You won’t see automobile or health supplement ads.

Our PROMISE: Quality Digest only displays static ads that never overlay or cover up content. They never get in your way. They are there for you to read, or not.

So please consider turning off your ad blocker for our site.

Thanks,
Quality Digest

About The Author

PharmaNet Development Group Inc.

PharmaNet Development Group Inc., a global drug development services company, provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug, and medical device industries. The company offers early- and late-stage consulting, Phase I clinical studies and bioanalytical analyses, and Phase II, III, and IV clinical development programs. With approximately 2,300 employees in 33 countries and more than 38 facilities throughout the world, PharmaNet is a recognized leader in outsourced clinical development.

Search

Quality Digest